Neuropace, Inc. NPCE Net proceeds from sales of subsidiary shares
Net proceeds from sales of subsidiary shares at other companies
Other financials
Where this comes from
Reported directly by Neuropace, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceInitialPublicOffering.
The official record: Neuropace, Inc.’s 10-K, filed March 4, 2025, on SEC EDGAR. View the filing →
Ask your AI about Neuropace, Inc.'s net proceeds from sales of subsidiary shares.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neuropace, Inc.'s net proceeds from sales of subsidiary shares?
- Neuropace, Inc. (NPCE) reported net proceeds from sales of subsidiary shares of $819.25K in Q4 2024.
- How has Neuropace, Inc.'s net proceeds from sales of subsidiary shares changed year-over-year?
- Neuropace, Inc.'s net proceeds from sales of subsidiary shares decreased by 58.5% year-over-year, from $1.97M to $819.25K.
- What is the long-term trend for Neuropace, Inc.'s net proceeds from sales of subsidiary shares?
- Over 2 years (2021 to 2024), Neuropace, Inc.'s net proceeds from sales of subsidiary shares has grown at a -82.7% compound annual growth rate (CAGR), from $109.09M to $3.28M.